Skip to main content
Inventiva logo

Inventiva — Investor Relations & Filings

Ticker · IVA ISIN · FR0013233012 LEI · 969500I9Y690B3FZW590 PA Manufacturing
Open in API
Filings indexed 686 across all filing types
Latest filing 2023-07-27 Earnings Release
Country FR France
Listing PA IVA

About Inventiva

https://inventivapharma.com/

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for diseases with significant unmet medical needs. The company's primary therapeutic areas include fibrotic diseases, lysosomal storage disorders, and oncology. Its lead product candidate, lanifibranor, is a pan-PPAR (peroxisome proliferator-activated receptor) agonist being evaluated in a pivotal Phase III clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). Lanifibranor is designed to address the key features of NASH, including steatosis, inflammation, ballooning, and fibrosis. The candidate has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) based on positive Phase IIb results.

Recent filings

Filing Released Lang Actions
Correction: Inventiva publie ses informations financières préliminaires du 1er semestre 2023¹ et fait un point sur ses activités
Earnings Release Classification · 99% confidence The document is titled "Inventiva publie ses informations financières préliminaires du 1er semestre 2023 et fait un point sur ses activités" (Inventiva publishes its preliminary financial information for the first half of 2023 and provides an update on its activities). It explicitly details preliminary financial results (cash, revenue, cash flow consumption) for the first half of 2023 (S1 2023) and provides an update on clinical trial progress (NATiV3, LEGEND). This content structure—a release of period-specific financial highlights combined with operational updates—is characteristic of an Earnings Release (ER). It is not the full, audited Annual Report (10-K) or a comprehensive Interim Report (IR), as it explicitly states the figures are 'preliminary' and focuses on key highlights rather than full statutory statements. It is also not a mere announcement of a report (RPA) because it contains the actual preliminary data. H1 2023
2023-07-27 French
Inventiva publie ses informations financières préliminaires du 1er semestre 2023¹ et fait un point sur ses activités
Earnings Release Classification · 99% confidence The document is titled "Inventiva publie ses informations financières préliminaires du 1er semestre 2023 et fait un point sur ses activités" (Inventiva publishes its preliminary financial information for the first half of 2023 and provides an update on its activities). It explicitly details preliminary financial results for the first half of 2023 (H1 2023), including cash position, revenue, and cash flow analysis for the period ending June 30, 2023. This content structure—a comprehensive summary of financial performance for a period shorter than a year (six months)—aligns perfectly with the definition of an Interim / Quarterly Report (IR). Although it only contains *preliminary* figures, the depth of the financial breakdown (cash flows, R&D spend, revenue drivers) goes beyond a simple Earnings Release (ER) which usually contains only key highlights. It is not a full Annual Report (10-K) as it covers only six months. It is also not a Report Publication Announcement (RPA) because it contains the actual financial data, not just an announcement that a report is available. H1 2023
2023-07-27 French
Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business update
Earnings Release Classification · 99% confidence The document is titled "Inventiva Reports Preliminary 2023 First-Half Financial Information and Business update". It explicitly details preliminary financial results for the first half of 2023 (H1 2023), including cash positions, revenues, and operating/investing/financing cash flows. This content structure—providing key financial figures and operational updates for a specific interim period (six months)—is characteristic of an Interim/Quarterly Report. Although it uses the term 'preliminary', the depth of financial detail provided (cash flow breakdown, revenue sources, R&D expense comparison) suggests it is more comprehensive than a simple Earnings Release (ER). It is not a full Annual Report (10-K). Since it covers a period shorter than a year (H1 2023), the most appropriate classification is Interim / Quarterly Report (IR). The document length is substantial (over 21,000 characters), ruling out the 'RPA' classification based on the 'MENU VS MEAL' rule. H2 2023
2023-07-27 English
Inventiva annonce la présentation d’un abstract scientifique lors de la 82nd Scientific Sessions of the American Diabetes Association
Environmental & Social Information Classification · 99% confidence The document is titled "Inventiva annonce la présentation d'un abstract scientifique lors de la 82nd Scientific Sessions of the American Diabetes Association" and details the selection of a scientific abstract for presentation at a medical conference. It discusses clinical trial data (NATIVE study, lanifibranor) and provides contact information typical of a corporate press release. The text explicitly uses the header "COMMUNIQUE DE PRESSE" (Press Release) multiple times. This type of announcement, focusing on scientific data presentation rather than financial results (ER), management changes (MANG), or regulatory filings (10-K/IR), is best classified as a general announcement or a specific type of investor/scientific update. Since it is a formal announcement about scientific progress and presentation, it aligns closely with an Investor Presentation (IP) or a general Regulatory Filing (RNS). Given the focus on scientific data presentation at a conference, it is a specific type of investor communication. However, it is not a full presentation deck (IP) but a news release announcing the abstract. It does not fit perfectly into the financial categories. Therefore, the most appropriate general category for a non-financial, non-management, non-legal press release announcing scientific progress is the fallback category, Regulatory Filings (RNS), as it is a formal communication to the market about company activities. Revisiting the definitions: It is not an ER (financial results), not an IP (investor presentation deck), and not an LTR (legal proceedings). It is a press release announcing scientific findings. While 'IP' might seem close, this is a text announcement, not the presentation itself. 'RNS' serves as the best fit for general corporate announcements that don't fit elsewhere.
2023-06-24 French
Inventiva announces the presentation of a scientific abstract at the 83rd Scientific Sessions of the American Diabetes Association
Regulatory Filings Classification · 99% confidence The document is titled with an announcement: "Inventiva announces the presentation of a scientific abstract at the 83rd Scientific Sessions of the American Diabetes Association". The content details the abstract selection, the scientific background of the drug lanifibranor, and the specific presentation details (date, time, poster ID). This is a press release announcing participation in a scientific conference and the presentation of research findings, not the full financial report (10-K), an interim report (IR), or a general earnings release (ER). It is an announcement related to scientific/clinical progress, which often falls under general investor relations communication. Since there is no specific category for 'Scientific Presentation Announcement', and it is a formal press release detailing company activities and future outlook (including forward-looking statements and contact information), it best fits the general regulatory announcement category, RNS, or potentially Investor Presentation (IP) if it were the presentation slides themselves. Given the format is a press release announcing the *presentation* of an abstract, and it is not a core financial filing, RNS (Regulatory Filings/General Announcement) is the most appropriate fallback, although it strongly relates to R&D progress which is often covered in Investor Presentations (IP). However, since it is a news release about an event, RNS is safer than IP (which usually implies the actual deck). Given the context of a biopharma company announcing abstract acceptance, this is a standard form of investor communication. I will classify it as RNS as it is a general regulatory/news announcement.
2023-06-24 English
Inventiva annonce les résultats positifs de l’étude clinique initiée par un investigateur évaluant lanifibranor chez des patients atteints de DT2 et NAFLD
Earnings Release Classification · 100% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and announces positive results from a clinical study evaluating the drug lanifibranor. It details efficacy data, secondary endpoints, safety profile, and includes quotes from management and the principal investigator. Crucially, it concludes by announcing a webcast/conference call for investors to discuss these results and provides registration links. This structure—a formal announcement of significant, time-sensitive operational/clinical news, followed by details and an invitation to discuss—is characteristic of an Earnings Release (ER) or a general press release announcing major operational news. Since it is a detailed announcement of clinical trial results, which often accompany or precede formal earnings reports, and it explicitly mentions an investor webcast, it fits best under the 'Earnings Release' category (ER) or potentially a Regulatory Filing (RNS) if it were a mandatory disclosure. Given the focus on financial/operational results and investor communication, ER is the most appropriate fit among the specific options, as it is not a full transcript (CT), a formal annual report (10-K), or just a notice of a report publication (RPA). The length (over 25k characters) confirms it is substantial content, not just a brief notice. FY 2023
2023-06-13 French

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.